Invivyd (IVVD) said Monday virology data supports its assertion its half-life extended investigational monoclonal antibody PEMGARDA, or pemivibart, is effective against current SARS-CoV-2 variant spike proteins.
Invivyd collaborates with LabCorp's Monogram Biosciences to monitor antiviral activity for independent virology assessments, and to deterime if its pemivibart potency needs to be changed as SARS-CoV-2 variants evolve.
Shares of the company were up 2.5% in recent Monday premarket activity.
Price: 1.2300, Change: +0.03, Percent Change: +2.50
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。